| abstract |
The present invention relates to the preparation of an anti-HCV compound (1aR, 5S, 8S, 9S, 10R, 22aR)-5-tertiary butyl-N-[(1R,2R)-2-(difluoromethyl)-1-{[ (1-Methylcyclopropyl)sulfonyl]amine-methylmethyl}cyclopropyl]-9-ethyl-18,18-difluoro-14-methoxy-3,6-di-oxy- 1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradehydro-8H-7,10-extended methylcyclopropane [18,19][1 , 10,3,6]dioxadiazacyclopentadecano[11,12-b]quinoxaline-8-carboxamide (Compound I) crystal form and its properties in the solid state:nâ–ˇnThe invention also provides a method of making the crystalline form and a method of using the crystalline form. |